Insight, China's Pharmaceutical Industry

Kexing Pharmaceutical and Sinotherapeutics Partner to Commercialize Tofacitinib Extended-Release Tablets in Kuwait and Mexico

Kexing Pharmaceutical (SHA: 688136) and Sinotherapeutics Inc. (SHA: 688247) have announced a joint commercialization agreement...

Company Deals

Genrix Bio Licenses BCMA×CD3 Bispecific Velinotamig to Fosun’s Yaopharma for Greater China in $268M Deal

Fineline Cube May 29, 2026

Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) announced a licensing agreement with Yaopharma Co.,...

Company Drug

Henlius Biotech Initiates China Dosing in Phase II/III Trial of Novel PD-L1 ADC HLX43 for Squamous NSCLC

Fineline Cube May 29, 2026

Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing in China for an...

Company Drug

Hengrui Pharmaceuticals Receives NMPA Approval to Study SHR-1819 in Pediatric Atopic Dermatitis, Challenging Sanofi’s Dupilumab

Fineline Cube May 29, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received approval from...

Company Drug

Sino Biopharmaceutical and GSK Report 19% Functional Cure Rate with Bepirovirsen in Phase III Hepatitis B Studies at EASL 2026

Fineline Cube May 29, 2026

Sino Biopharmaceutical Limited (HKG: 1177) announced positive results from two Phase III clinical studies, B-Well...

Company Drug

Konruns Pharmaceutical to Present Promising Phase II KC1036 Data in Advanced Thymic Tumors at ASCO 2026

Fineline Cube May 29, 2026

Konruns Pharmaceutical Co., Ltd. (SHA: 603590) announced plans to present results from a Phase II...

Company Deals

Innovent Biologics and Pfizer Forge $10.5B Global Oncology Partnership Spanning 12 First-in-Class Programs

Fineline Cube May 29, 2026

Innovent Biologics (HKG: 1801) and Pfizer (NYSE: PFE) have announced a landmark $10.5 billion global...

Company Deals

YolTech Therapeutics Secures $500M Series C Financing to Advance In Vivo Gene-Editing Pipeline Including China’s First LNP-Based Therapy

Fineline Cube May 29, 2026

YolTech Therapeutics, a China-based biotechnology company founded in 2021, announced the completion of a $500...

Policy / Regulatory

China’s NHSA Proposes First National Basic Medical Insurance Medical Service Items List to Standardize Reimbursement Framework

Fineline Cube May 29, 2026

China’s National Healthcare Security Administration (NHSA) has released a draft proposal titled “Work Plan for...

Company Drug

J&J Secures FDA Approval for TREMFYA Label Expansion to Include Structural Joint Damage Inhibition in Psoriatic Arthritis

Fineline Cube May 29, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA)...

Others

Suzhou Ribo Life Science Files Phase II EMA Application for RBD1119 – Novel siRNA Antithrombotic for Coronary Artery Disease

Fineline Cube May 29, 2026

Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced it has submitted a Phase II...

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Fineline Cube May 28, 2026

LongBio Pharma, a China-based clinical-stage biopharmaceutical company focused on biomacromolecule therapeutics for allergic and autoimmune...

Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Fineline Cube May 28, 2026

Antengene Corporation Limited (HKG: 6996) announced that China’s National Medical Products Administration (NMPA) has granted...

Company

J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market

Fineline Cube May 28, 2026

Johnson & Johnson Innovative Medicine and Novartis China have announced significant leadership and organizational changes...

Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Fineline Cube May 28, 2026

Sino Biopharmaceutical Limited (HKG: 1177) announced the presentation of first-in-human Phase I clinical study results...

Company Drug

Dizal Pharmaceutical’s Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC – Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy

Fineline Cube May 28, 2026

Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that China’s Center for Drug Evaluation (CDE) has...

Company Deals

Lantheus Holdings Receives $7 Billion Buyout Offer from Curium Pharma – Radiopharmaceutical Leader’s Alzheimer’s Portfolio Attracts Strategic Interest

Fineline Cube May 28, 2026

Lantheus Holdings, Inc. (NASDAQ: LNTH) is considering a buyout offer from French company Curium Pharma,...

Company

VectorBuilder Commits $50 Million to Chicago Biomanufacturing Hub – Integrated R&D and GMP Facility to Streamline Gene Delivery Product Development

Fineline Cube May 28, 2026

VectorBuilder, a China-based gene delivery technology developer, announced plans to invest USD 50 million to...

Company Drug

SciClone Pharmaceuticals Launches Vibativ in China – Dual-Mechanism Glycopeptide Antibiotic Offers Enhanced MRSA Treatment with Once-Daily Dosing

Fineline Cube May 28, 2026

SciClone Pharmaceuticals Inc. announced the commercial launch of Vibativ (telavancin) in China, following its regulatory...

Company Medical Device

Roche Launches Liver Disease Panel – Digital Algorithms Combine Biomarker Diagnostics with CE-Certified LiverPRO to Transform Chronic Liver Disease Management

Fineline Cube May 28, 2026

Roche Holding AG (SWX: ROP, OTCMKTS: RHHBY) announced the launch of its Liver Disease Panel,...

Insight, China's Pharmaceutical Industry

Lundbeck Partners with Cradle to Deploy AI-Guided Protein Engineering for CNS Antibody Discovery

Medtronic Makes Strategic ICE Catheter Investments to Strengthen Cardiac Ablation Leadership and Affera Ecosystem Integration

Regeneron Expands CytomX Partnership to $4 Billion in Potential Milestones for Conditionally-Activated Bispecific Cancer Therapies

Ascidian Therapeutics Partners with Eli Lilly in $1.9 Billion RNA Exon Editing Deal for Monogenic Kidney Diseases

Shandong Boan Biotech Licenses BA5101 Dulaglutide Biosimilar for US Market – First Global Copycat of Trulicity

Hansoh Pharmaceutical’s Olatorepatide GLP-1/GIP Dual Agonist Accepted for NMPA Review for Weight Management Indication

Johnson & Johnson’s Nipocalimab (Imaavy) Demonstrates Efficacy in Phase II JASMINE Study for Systemic Lupus Erythematosus, First FcRn Blocker to Show Success in SLE

Kexing Pharmaceutical and Sinotherapeutics Partner to Commercialize Tofacitinib Extended-Release Tablets in Kuwait and Mexico

Genrix Bio Licenses BCMA×CD3 Bispecific Velinotamig to Fosun’s Yaopharma for Greater China in $268M Deal

Henlius Biotech Initiates China Dosing in Phase II/III Trial of Novel PD-L1 ADC HLX43 for Squamous NSCLC

Hengrui Pharmaceuticals Receives NMPA Approval to Study SHR-1819 in Pediatric Atopic Dermatitis, Challenging Sanofi’s Dupilumab

Sino Biopharmaceutical and GSK Report 19% Functional Cure Rate with Bepirovirsen in Phase III Hepatitis B Studies at EASL 2026

Konruns Pharmaceutical to Present Promising Phase II KC1036 Data in Advanced Thymic Tumors at ASCO 2026

Innovent Biologics and Pfizer Forge $10.5B Global Oncology Partnership Spanning 12 First-in-Class Programs

YolTech Therapeutics Secures $500M Series C Financing to Advance In Vivo Gene-Editing Pipeline Including China’s First LNP-Based Therapy

China’s NHSA Proposes First National Basic Medical Insurance Medical Service Items List to Standardize Reimbursement Framework

J&J Secures FDA Approval for TREMFYA Label Expansion to Include Structural Joint Damage Inhibition in Psoriatic Arthritis

Suzhou Ribo Life Science Files Phase II EMA Application for RBD1119 – Novel siRNA Antithrombotic for Coronary Artery Disease

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Dizal Pharmaceutical’s Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC – Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy

Lantheus Holdings Receives $7 Billion Buyout Offer from Curium Pharma – Radiopharmaceutical Leader’s Alzheimer’s Portfolio Attracts Strategic Interest

VectorBuilder Commits $50 Million to Chicago Biomanufacturing Hub – Integrated R&D and GMP Facility to Streamline Gene Delivery Product Development

SciClone Pharmaceuticals Launches Vibativ in China – Dual-Mechanism Glycopeptide Antibiotic Offers Enhanced MRSA Treatment with Once-Daily Dosing

Roche Launches Liver Disease Panel – Digital Algorithms Combine Biomarker Diagnostics with CE-Certified LiverPRO to Transform Chronic Liver Disease Management

You Missed

Hansoh Pharmaceutical’s Olatorepatide GLP-1/GIP Dual Agonist Accepted for NMPA Review for Weight Management Indication

Johnson & Johnson’s Nipocalimab (Imaavy) Demonstrates Efficacy in Phase II JASMINE Study for Systemic Lupus Erythematosus, First FcRn Blocker to Show Success in SLE

Lundbeck Partners with Cradle to Deploy AI-Guided Protein Engineering for CNS Antibody Discovery

Novo Nordisk Launches Wegovy Oral Tablets in UAE – First International Market Outside US for Semaglutide Weight Management Therapy